Full Press Release Details
Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System
continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set
for the treatment of carotid artery disease and the prevention of stroke
Aviv, Israel, and Miami, Florida - December 20, 2023 - InspireMD (Nasdaq: NSPR), developer of the CGuard
Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled,
"Shunts with Blood Flow Indicators."
patent covers key aspects of the company's SwitchGuardTM Neuroprotection System (NPS) along with future features in
development that are expected to enable the treating physician to visualize flow through the system. The SwitchGuardTM NPS
is designed to allow the physician to reverse blood flow to the brain during a carotid artery stenting procedure, including Transcarotid
Artery Revascularization (TCAR) or other neurovascular procedures. The SwitchGuardTM NPS is designed to prevent embolic debris
generated during the procedure from traveling to the brain, passing the blood through the filter housed within the SwitchGuard before
returning it to the patient, to minimize blood loss during the procedure.
October 2023, the Centers for Medicare and Medicaid Services (CMS) expanded coverage for carotid artery stenting (CAS) and TCAR to include
both asymptomatic and standard risk patients at either high- or standard- risk for carotid endarterectomy (surgery). The broader availability
of these less invasive options should better enable physicians to tailor treatment plans to the needs of individual patients.
Slosman, Chief Executive Officer of InspireMD, stated, "The issuance of this patent demonstrates our continued priority to
develop and build on our robust intellectual property to support our innovations, while expanding our product portfolio for optimal patient
outcomes in the treatment of carotid artery disease with the utmost safety in mind. This coupled with our CGuard Prime Carotid Stent
System should provide clinicians with innovation and safety during carotid revascularization procedures and minimize the risk of stroke."
expects to submit an Investigational Device Exemption (IDE) to the FDA in 2024, which, if approved, would allow the company to initiate
a clinical trial to support the clearance of the SwitchGuardTM NPS coupled with CGuard Prime.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing
outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the
routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements
regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such
statements may be preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential", "scheduled" or similar words. Examples of such statements include, but are
not limited to, statements relating to the C-GUARDIANS U.S. IDE clinical trial, including 30-day results from such trial, as well as
the timing and outcome of any subsequent results, the EFS, PMA or potential launch. Forward-looking statements are not guarantees of
future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which
are beyond the company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments
and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding
our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and
such capital raising may be costly or difficult to obtain and could dilute out stockholders' ownership interests; market acceptance
of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results
or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate
revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual
property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards
and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient
to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry,
with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing,
marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological
obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier;
technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies
and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to
successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal,
state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct
business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications
challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation
of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and
market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information
about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's
filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly
Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at
http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Padala, Managing Director